Elite in Ulcerative Colitis

Fernando J. Bermejo-Jose

Fuenlabrada, MD, ES 
Elite in Ulcerative Colitis
Fuenlabrada, MD, ES 
OverviewLocationsClinical Research

Overview

Fernando Bermejo-Jose practices in Fuenlabrada, Spain. Mr. Bermejo-Jose is rated as an Elite expert by MediFind in the treatment of Ulcerative Colitis. His top areas of expertise are Viral Gastroenteritis, Colitis, Crohn's Disease, Colonoscopy, and Endoscopy.

His clinical research consists of co-authoring 143 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 39 articles and participated in 1 clinical trial in the study of Ulcerative Colitis.

Gender
Male

Locations

Fuenlabrada, MD, Spain
Other Locations
Santiago De Compostela, GA, Spain
La Paz, MD, Spain
Madrid, MD 28942, Spain
Cuenca, CM 16071, Spain
La Paz, CN, Spain
Serrano, MD 28006, Spain
Spain

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

3-Arm Randomized Placebo Controlled Double Blind Phase 3 Study to Evaluate Safety and Efficacy of Once-Daily and Twice-Daily Hydrocortisone Acetate 90 mg Suppository Administered With a Sephure Applicator in Subjects With Ulcerative Colitis
3-Arm Randomized Placebo Controlled Double Blind Phase 3 Study to Evaluate Safety and Efficacy of Once-Daily and Twice-Daily Hydrocortisone Acetate 90 mg Suppository Administered With a Sephure Applicator in Subjects With Ulcerative Colitis
Enrollment Status: Completed
Publish Date: July 30, 2025
Intervention Type: Combination product
Study Drug: Hydrocortisone acetate suppository administered with Sephure applicator
Study Phase: Phase 3
A Phase-III, Randomized, Double-blind, Parallel-group, Placebo-controlled, International, Multicentre Study to Assess Efficacy and Safety of Cx601, Adult Allogeneic Expanded Adipose-derived Stem Cells (eASC) for the Treatment of Complex Perianal Fistula(s) in Patients With Crohn's Disease Over a Period of 24 Weeks and a Follow-up Period up to 52 Weeks
A Phase-III, Randomized, Double-blind, Parallel-group, Placebo-controlled, International, Multicentre Study to Assess Efficacy and Safety of Cx601, Adult Allogeneic Expanded Adipose-derived Stem Cells (eASC) for the Treatment of Complex Perianal Fistula(s) in Patients With Crohn's Disease Over a Period of 24 Weeks and a Follow-up Period up to 52 Weeks
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Drug, Other
Study Drug: Cx601
Study Phase: Phase 3
Prospective, Phase II, Randomized, Open-label, Parallel Group Study to Evaluate the Efficacy of Baricitinib, Imatinib or Supportive Treatment in Patients With SARS Cov2 Pneumonia
Prospective, Phase II, Randomized, Open-label, Parallel Group Study to Evaluate the Efficacy of Baricitinib, Imatinib or Supportive Treatment in Patients With SARS Cov2 Pneumonia
Enrollment Status: Unknown
Publish Date: August 03, 2021
Intervention Type: Other, Drug
Study Drugs: Imatinib, Baricitinib
Study Phase: Phase 2
A Prospective Study on the Incidence and Risk Factors Related to Infection in Patients With Inflammatory Bowel Disease
A Prospective Study on the Incidence and Risk Factors Related to Infection in Patients With Inflammatory Bowel Disease
Enrollment Status: Completed
Publish Date: July 23, 2020
View 3 Less Clinical Trials

143 Total Publications

Comprehensive proteomic profile in newly diagnosed patients with inflammatory bowel disease: identification of potential biomarkers.
Comprehensive proteomic profile in newly diagnosed patients with inflammatory bowel disease: identification of potential biomarkers.
Journal: Journal of Crohn's & colitis
Published: October 09, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Bermejo-Jose's expertise for a condition
ConditionClose
View All 9 Advanced Conditions
View All 13 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile